TKM 130803

Drug Profile

TKM 130803

Alternative Names: siEbola-3 - Arbutus Biopharma; TKM-130803; TKM-Ebola-Guinea

Latest Information Update: 29 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tekmira Pharmaceuticals Corporation
  • Developer Arbutus Biopharma; University of Oxford
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Ebola virus infections

Most Recent Events

  • 25 Oct 2016 Suspended - Phase-II for Ebola virus infections in Sierra Leone (IV, Infusion) (Arbutus Biopharma pipeline; October 2016)
  • 25 Oct 2016 Efficacy and safety data from the phase II RAPID-TKM trial in Ebola virus infections released by Arbutus Biopharma
  • 19 Apr 2016 Arbutus Biopharma terminates the phase II RAPID-TKM trial in Ebola virus infections in Sierra Leone due to futility rule (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top